CFO Jane Pritchett Henderson adds CBO role; salary increased to $510,000

Invivyd, Inc.

Jane Pritchett Henderson appointed Chief Business Officer while remaining CFO; base salary raised to $510,000.
Annual meeting set for May 26, 2022, to be held virtually.
Henderson's amended employment agreement includes nine months' severance for termination without cause or for good reason.
Unvested time-based equity awards get 90-day delayed forfeiture; accelerate upon change in control if definitive agreement signed.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jane Pritchett Henderson

Chief Business Officer

IVVD · Invivyd, Inc.

Effective: 2022-03-18
Filed: March 21, 2022, 7:59 PM ET

On March 18, 2022, the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Jane Pritchett Henderson, the Company’s principal financial officer, to serve as the Company’s Chief Business Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jane Pritchett Henderson was appointed as Chief Business Officer at Invivyd, Inc..

Action: appointed
Role: Chief Business Officer

Exact text from the filing

On March 18, 2022, the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Jane Pritchett Henderson, the Company’s principal financial officer, to serve as the Company’s Chief Business Officer.

View on SEC.gov

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-080001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.